Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 3/20 | 0.36 |
| ▸ | CASP1 | P29466 | 2/20 | 0.36 |
| ▸ | CASP7 | P55210 | 2/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TYMS | P04818 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8712256 | 0.82 | MAPK1 (0.47) | MEN1KMT2AMAPK1MAPTALDH1A1 | |
| SCHEMBL6540748 | 0.79 | MAPK1 (0.50) | MEN1KMT2AMAPK1MAPTALDH1A1 | |
| SCHEMBL3406520 | 0.75 | MEN1 (0.47) | MEN1KMT2AMAPK1MAPTALDH1A1 | |
| SCHEMBL778669 | 0.74 | MAPK1 (0.50) | MEN1KMT2AMAPK1MAPTALDH1A1 | |
| SCHEMBL3406240 | 0.72 | MAPT (0.45) | MEN1KMT2AMAPK1MAPTALDH1A1 | |
| SCHEMBL953862 | 0.72 | MAPK1 (0.56) | MEN1KMT2AMAPK1MAPTALDH1A1 | |
| SCHEMBL23300524 | 0.71 | MAPT (0.50) | MEN1KMT2AMAPK1MAPTALDH1A1 | |
| SCHEMBL6154836 | 0.71 | MAPK1 (0.43) | MEN1KMT2AMAPK1MAPTALDH1A1 | |
| SCHEMBL779663 | 0.69 | MAPK1 (0.53) | MEN1KMT2AMAPK1MAPTALDH1A1 | |
| SCHEMBL8332159 | 0.69 | MEN1 (0.41) | MEN1KMT2AMAPK1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253633-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-20100183604-A1 | PREVENTIVE/REMEDY FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-22 | — | — | US | disclosed |
| EP-2163258-A1 | PREVENTIVE/REMEDY FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
| US-20090233937-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183604-A1 | PREVENTIVE/REMEDY FOR CANCER | CFL1, LIMK1, LIMK2 | MEN1 436/4885KMT2A 1729/4885MAPK1 162/4885 |
| US-20090233937-A1 | FUSED HETEROCYCLIC COMPOUND | ROS1, JAK2, ERBB2 | MEN1 2485/4885KMT2A 382/4885MAPK1 86/4885 |
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | MEN1 2063/4885KMT2A 300/4885MAPK1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.